Use of A2A adenosine receptor agonists

Details Use of A2A adenosine receptor agonists Use of A2A adenosine receptor agonists

2005-10-19

2010-02-02

Crane, Lawrence E (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07655636

ABSTRACT:
The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, — an adenosine A2Areceptor agonist — to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.

REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5032252 (1991-07-01), Owen et al.
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5270304 (1993-12-01), Kogi et al.
patent: 5459254 (1995-10-01), Yamaguchi et al.
patent: 5593975 (1997-01-01), Cristalli
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5705491 (1998-01-01), Yamada
patent: 5770716 (1998-06-01), Khan et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5939543 (1999-08-01), Morozumi et al.
patent: 6026317 (2000-02-01), Verani
patent: 6214807 (2001-04-01), Zablocki
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6322771 (2001-11-01), Linden et al.
patent: 6368573 (2002-04-01), Leung
patent: 6403567 (2002-06-01), Zablocki
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6552023 (2003-04-01), Zablocki
patent: 6599283 (2003-07-01), Marzilli et al.
patent: 6605597 (2003-08-01), Zablocki et al.
patent: 6642210 (2003-11-01), Zablocki et al.
patent: 6677336 (2004-01-01), Zablocki et al.
patent: 6770634 (2004-08-01), Zablocki et al.
patent: 6855818 (2005-02-01), Zablocki et al.
patent: 7144872 (2006-12-01), Zablocki et al.
patent: 2002/0012946 (2002-01-01), Belardinelli et al.
patent: 2002/0111327 (2002-08-01), Linden et al.
patent: 2002/0147174 (2002-10-01), Jones et al.
patent: 2004/0038928 (2004-02-01), Zablocki et al.
patent: 2004/0064039 (2004-04-01), Belardinelli
patent: 2004/0127533 (2004-07-01), Hart
patent: 2004/0198692 (2004-10-01), Zablocki et al.
patent: 2005/0020915 (2005-01-01), Belardinelli et al.
patent: 2005/0175535 (2005-08-01), Belardinelli et al.
patent: 2007/0299089 (2007-12-01), Belardinelli
patent: 2008/0170990 (2008-07-01), Lieu et al.
patent: 2008/0213165 (2008-09-01), Lieu et al.
patent: 2008/0267861 (2008-10-01), Lieu et al.
patent: 965411 (1975-04-01), None
patent: 0 354 638 (1990-02-01), None
patent: S48-26038 (1973-08-01), None
patent: HEI 5[1993]-9197 (1993-01-01), None
patent: WO 93/25677 (1993-12-01), None
patent: WO 98/52611 (1998-11-01), None
patent: WO 98/57651 (1998-12-01), None
patent: WO 99/63938 (1999-12-01), None
patent: WO 00/78778 (2000-12-01), None
patent: WO 00/78779 (2000-12-01), None
patent: WO 01/62979 (2001-08-01), None
patent: WO 2004/011010 (2004-02-01), None
patent: WO 2005/082379 (2005-09-01), None
Xu et al., “Coronary Vasodilation by a Short Acting, Low Affinity A2A Adenosine Receptor Agonist in Anesthetized Closed Chest Dogs: A Second Generation of Coronary Artery Pharmacologica Stressor”, Circulation, vol. 102, No. 18, pp. 3912 (2000).
Iskandrian A., “Adenosine Myocardial Perfusion Imaging”, The Journal of Nuclear Medicine, vol. 35, pp. 734-736 (1994).
Gao et al., “Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation Inverse Relationship between Affinity and Duration of Action of A2A Agonists”, Journal of Pharmacology and Experimental Therapeutics, vol. 928, pp. 209-218 (2001).
Marumoto, et al., “Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines”, Chem.. Pharm. Bull. 23(4): 759-774 (1975).
Marumoto, et al., “Synthesis and Enzymatic Activity of Adenosine 3′,5′-Cyclic Phosphate Analogs”, Chem.. Pharm. Bull. 27(4) 990-1003 (1979).
Persson, et al., “Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives”, Bioorganic & Medicinal Chemistry, 3:1377-1382 (1995).
Mager, et al., “Molecular simulation applied to 2-(N′alkylidenehydrazino)- and 2-(N′-aralkylidenehydrazino) adenosine A2 Agnonists”, Eur J. Med. Chem, 30:15-25 (1995).
Cristalli et al., “2-Alkynl Derivatives of Adenosine 5′-N′ethyluronamide: Selective A2 Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation”, J. Med. Chem, 37:1720-1726 (1994).
Matsuda, et al., “Nucleosides and Nucleotides. 103. 2-Alkynyladenoines: A Novel Class of Selective Adenosine A2 Receptor Agonists with Potent Antihypertensive Effects”, J. Med. Chem. 35:241-252 (1992).
Glover et al. “Pharmacological Stress Thallium Scintigraphy with 2-Cyclohexylmethylidenehydrazinoadenosine”, Circulation, pp. 1726-1732 (1996), V. 94.
Glover et al. “Characterization of a New, Highly Selective Adenosine A2A Receptor/Agonists with Potential Use in Pharmacologic Stress Perfusion Imaging”, Circulation, vol. 110, pp. I-311 (1999), (Abstract No. 1626).
Cerqueira, “The Future of Pharmacologic Stress: Selective A2A Adenosine Receptor Agonists”, American Journal of Cardiology, pp. 33D-40D (2004) , V. 94(2A), Feb. 22, 2004.
Kerensky et al., “Dose Dependent Increase in Human Coronary Blood Flow Velocity Following an IV Bolus of CVT-3146, a Novel A2A Adenosine Receptor Agonist: A Potential Agent for the Use in Pharmacological Stress Testing for Myocardial Perfusion Imaging”, Circulation, Supplement II, vol. 106, p. II-618 (2002), Abstr. No. 3054.
Hendel et al., “Pharmacologic Stress SPECT Myocardial Perfusion Imaging with a Selective A2A Agonist: Results of a Pilot Study Comparing Adenosine with CVT-3146”, Circulation, Supplement IV, vol. 108, p. IV-636 (2003), Abstr. No. 2892.
U.S. Appl. No. 11/522,120, filed Sep. 15, 2006, Elzein et al.
U.S. Appl. No. 11/588,834, filed Oct. 27, 2006, Zablocki et al.
Office Action issued by the USPTO for U.S. Appl. No. 09/338,327 on Jun. 20, 2000.
Response to Jun. 20, 2000 Office Action for U.S. Appl. No. 09/338,327.
Office Action issued by the USPTO for U.S. Appl. No. 09/812,176 on Jun. 5, 2001.
Response to the Jun. 5, 2001 Office Action for U.S. Appl. No. 09/812,176.
Office Action issued by the USPTO for U.S. Appl. No. 10/018,758 on May 22, 2003.
Amendment Under 37 CFR 1.111 in response to Office Action of May 22, 2003 for U.S. Appl. No. 10/018,758.
Final Office Action issued by the USPTO for U.S. Appl. No. 10/018,758 on Nov. 4, 2003.
Preliminary Amendment filed on Mar. 30, 2004 for U.S. Appl. No. 10/813,535.
Office Action issued by the USPTO for U.S. Appl. No. 10/813,535 on Nov. 23, 2005.
Response to the Nov. 23, 2005 Official Action for U.S. Appl. No. 10/813,535.
Preliminary Amendment filed on Jul. 6, 2001 for U.S. Appl. No. 09/792,617.
Office Action issued by the USPTO for U.S. Appl. No. 09/792,617 on Sep. 27, 2002.
Response to Sep. 27, 2002 Restriction Requirement for U.S. Appl. No. 09/792,617.
Office Action issued by the USPTO for U.S. Appl. No. 09/796,617 on Jan. 7, 2003.
Office Action issued by the USPTO for U.S. Appl. No. 10/614,702 on Sep. 16, 2004.
Hendel et al. “Initial Clinical Experience with Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging”, Journal of the American College of Cardiology, vol. 46, No. 11, pp. 2069-2075 (Dec. 6, 2005).
Korolkovas, Essentials of Molecular Pharmacology-Background for Drug Design, Wiley—Interscience, New York, NY, 1970, only pp. 266-272 supplied.
Kusmic et al., “Coronary microcirculatory vasoconstriction induced by low-flow ischemia in mouse hearts is reversed by an A2A adenosine receptor”, FASEB Journal, Apr. 2007, A1227-A1228

Affiliated with

Also associated with

Rating

Use of A2A adenosine receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of A2A adenosine receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of A2A adenosine receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4200530